(~1.1'3) and int,erferon-y ( TFNy) . acting on human hepatoma cells (IIepGZ,Hep?B) , directly mediated changes in expression of several plasma proteins, characteristic of the acute phase response. Recombinant human IL-16 or TNFa increased steady state levels of mRMA for and rate of synthesis of complement proteins C3, factor R , a-l-antichymotrypsin and decreased steady state levels of mRDIA for and rate of synthesis of albumin and transferrin in 1IepC2 and Uep3B cells. Recombinant human IFNy increased steady state levels of mRNA for and rate of synthesis of IL-1-and l' P!punresponsive complement protein ~4 . Pecombinant human IL-2 also elicit,ed hepatic acute phase gene expression but throuah an indirect pathway involvin~ the induction of monocyte IL-1 release. The effect of these cyt.okines on hepatic acute phase Eenes (factor B, C4) was also evident in mouse fibroblasts transfected with the cloned human factor B or C4 genes suggesting the presence of regulatory elements within the gene or its flanking regions. These results indicate that the human hepatic acute phase response can be studied in a human hepatoma cell with t,he use of well-characterized and highly purified cytokines. In vivo. hepat,ic acute phase gene expression is likely to involve -- Adverse hematologic reactions to 2 therapy have been well-documented in isolated IBD patients. In prior reports, hemolysis has been noted to be infrequent, and has occurred within 2-4 weeks of initiation OF therapy or coincident with an increase in dosage. Most have been receiving generally high dosages (>4g/day). These toxic manifestations are generally belicved to be associated with a slow-acetylator phenotype. After diagnosing three individuals with ?-induced hemolytic anemia occurring from 2 to 30 months after the initiation of therapy, we undertook to study the prevalence of 5-induced hemolysis in a group of IBD patients (3-19 y.0.) without evidence of active GI blood loss. Out of 20 patients (15 U.C., 5 Crohn's), nine (45%) exhibited evidence of hemolysis by reticulocyte count (average 6.9%. range 2.4-12.8%) and haptoglobin level (average 10 mg/dl, range 0-30, nl 100-300 mgldl). The average dosage was only 50 mg/ kg/day with a maximum of 3glday. Upon cessation of 2, hemolysis promptly resolved and the hemoglobin level increased an average of 2.lg/d. Prior observation of this hemolysis was obscured by the common occurrence of anemia and reticulocytosis in IBD, and by the laboratory variability in measurement of reticulocyte count.
We conclude that in pediatric IBD patients ?-induced hemolysis is common, often late in onset, and occurs with modest dosages. Patients on 5-therapy should be followed with routine reticulocyte counts and haptoglobin levels as long as therapy persists. A number of investigators have assessed the activity of IBD through the fecal clearance of a -AT.al-AT is a serine protease inhibitor present in the eel-globulin fraction of blood.In our investigations in IBD,we have found that the simple and rapid determination of serum al-AT alone gave a useful measure of disease activity.We compared the sensitivity and specificity of serum al-AT levels versus ESR's in 1)the initial diagnosis of IBD and 2)the evaluation of disease activity in patients with known 1BD.Serum al-AT was meL~sured by radial immunodiffusion (elevated 2350 ug/dl),and ESR by the Westergren method (elevated >20 mm/hr).Diagnosis and disease activity was determined by accepted clinical,endoscopic,radiologicCand histologic methods.
( 1) 29/49 (59%) 29/29(100%) For the initial presentation (l),al-AT was elevated in 93% of patients vs 53% with elevated ESR.Both tests were relatively specific (92% vs 100%) for patients without IBD.In the evaluation of disease activity,al-AT was elevated 98% of the time vs 59% for ESR during active disease.Both were normal in inactive disease. Analysis with respect to sex or IBD-type (U.C. vs Crohn's) yielded similar findings.Conc1usions:Serum al-AT is a better indicator of IBD activity than the commonly used ESR.We suggest that al-AT determination be used both in the diagnosis and follow-up of patients with ISD. The prevalence in the German group was 105/100.00O, and 33/100.000 in the Italian group. HLA-typing was performed in 40 patients and in 50 Cerman and 50 Italian controls. Forty-three percent of the CD patients were positive for R8, R5Z for nR3, 64% for nR7 and 5hXEor DR317. Nu difFerence in the expression of H1.A R8, nR3, nR7 was fount1 in the Italian and Cerman controls. Seventeen percent in hoth control groups were positlve for HLA RR, 35% for HLA nR3 and 30% For HLA nR7
CLINICAL BENEFITS OF CO-INFUSING A LIPID EMULSION WITH AMINO ACIDS-DEXTROSE SOLUTIONS IN NEWBORN IN-
Conclusions: The prevalence of the disease in two ethnic groups living under similar environmental condidons was significantly different. The data presented here strongly suggests that there is no association hetween the prevalence of the disease and HLA-type in this populntion study. Further from preliminary data it may be postulated that the age of introduciton of gluten to the infant diet may affect the prevalence of coeliac disease.
